Surveillance over cytomegalovirus (CMV) reactivation following hematopoietic stem cell transplantation: a single-center experience

References

• Manicklal S, Emery VC, Lazzarotto T, et al. The ‘silent’ global burden of congenital cytomegalovirus. Clin Microbiol Rev. 2013;26(1):1–6. doi: 10.1128/CMR.00062-12.
   Web of Science ®Google Scholar
• Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202(5):673–685. doi: 10.1084/jem.20050882.
   PubMed Web of Science ®Google Scholar
• Kim J, Kim A-R, Shin E-C. Cytomegalovirus infection and memory T cell inflation. Immune Netw. 2015;15(4):186–190. doi: 10.4110/in.2015.15.4.186.
   PubMed Web of Science ®Google Scholar
• Jerry Teng CL, Wang PN, Chen YC, et al. Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: a mini-review. J Microbiol Immunol Infect. 2021;54(3):341–348. Jun 1 doi: 10.1016/j.jmii.2021.01.001.
   PubMedGoogle Scholar
• Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427–2438. doi: 10.1182/blood-2015-11-679639.
   PubMed Web of Science ®Google Scholar
• Niederwieser D, Baldomero H, Bazuaye N, et al. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica. 2022;107(5):1045–1053. doi: 10.3324/haematol.2021.279189.
   PubMed Web of Science ®Google Scholar
• Hatzimichael E, Tuthill M. Hematopoietic stem cell transplantation. Stem Cells Cloning. 2010;3(1):105–117. doi: 10.2147/SCCAA.S6815.
   PubMedGoogle Scholar
• Chaer FE, Shah DP, Chemaly RF. How I treat how I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. Blood. 2016;128(23):2624–2636. doi: 10.1182/blood-2016-06-688432.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Nichols WG, Papanicolaou G, et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003;9(9):543–558. doi: 10.1016/s1083-8791(03)00287-8.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113(23):5711–5719. doi: 10.1182/blood-2008-10-143560.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Nichols WG, Chemaly RF, et al. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized controlled trial. Ann Intern Med. 2015;162(1):1–10. doi: 10.7326/M13-2729.
   PubMed Web of Science ®Google Scholar
• Sourisseau M, Faure E, Béhal H, et al. The promising efficacy of a risk-based letermovir use strategy in CMV-positive allogeneic hematopoietic cell recipients. Blood Adv. 2023;7(5):856–865. doi: 10.1182/bloodadvances.2022008667.
   PubMed Web of Science ®Google Scholar
• Stoykova Z, Ivanova LI, Todorova TT, et al. Seroprevalence of cytomegalovirus in the North-Eastern bulgarian population, 2003-2015. ACTA Microbiol Bulg. 2016;32(3):27–32.
   Google Scholar
• Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101(2):407–414. doi: 10.1182/blood-2002-03-0993.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011;25(1):151–169. doi: 10.1016/j.hoc.2010.11.011.
   PubMed Web of Science ®Google Scholar
• Bordon V, Bravo S, Van Renterghem L, et al. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease. Transpl Infect Dis. 2008;10(1):19–23. doi: 10.1111/j.1399-3062.2007.00242.x.
   PubMed Web of Science ®Google Scholar
• Craddock C, Szydlo RM, Dazzi F, et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. Br J Haematol. 2001;112(1):228–236. doi: 10.1046/j.1365-2141.2001.02519.x.
   PubMed Web of Science ®Google Scholar
• Erard V, Guthrie K, Riddell S, et al. Impact of HLA A2 and cytomegalovirus serostatus on outcomes in patients with leukemia following matched-sibling myeloablative allogeneic hematopoietic cell transplantation. Haematologica. 2006;91(10):1377–1383.
   PubMed Web of Science ®Google Scholar
• Moins-Teisserenc H, Busson M, Scieux C, et al. Patterns of cytomegalovirus reactivation are associated with distinct evolutive profiles of immune reconstitution after allogeneic hematopoietic stem cell transplantation. J Infect Dis. 2008;198(6):818–826. doi: 10.1086/591185.
   PubMed Web of Science ®Google Scholar
• Ganepola S, Gentilini C, Hilbers U, et al. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation. Bone Marrow Transplant. 2007;39(5):293–299. doi: 10.1038/sj.bmt.1705585.
   PubMed Web of Science ®Google Scholar
• Ozdemir E, Saliba RM, Champlin RE, et al. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies. Bone Marrow Transplant. 2007;40(2):125–136. doi: 10.1038/sj.bmt.1705699.
   PubMed Web of Science ®Google Scholar
• Marty FM, Bryar J, Browne SK, et al. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood. 2007;110(2):490–500. doi: 10.1182/blood-2007-01-069294.
   PubMed Web of Science ®Google Scholar
• Gimeno C, Solano C, Latorre JC, et al. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. J Clin Microbiol. 2008;46(10):3311–3318. doi: 10.1128/JCM.00797-08.
   PubMed Web of Science ®Google Scholar
• Choi SM, Lee DG, Lim J, et al. Comparison of quantitative cytomegalovirus real-time PCR in whole blood and pp65 antigenemia assay: clinical utility of CMV real-time PCR in hematopoietic stem cell transplant recipients. J Korean Med Sci. 2009;24(4):571–578. doi: 10.3346/jkms.2009.24.4.571.
   PubMed Web of Science ®Google Scholar
• Ruell J, Barnes C, Mutton K, et al. Active CMV disease does not always correlate with viral load detection. Bone Marrow Transplant. 2007;40(1):55–61. doi: 10.1038/sj.bmt.1705671.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kanda Y, Kami M, et al. Monitoring cytomegalovirus infection by antigenemia assay and two distinct plasma real-time PCR methods after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;30(5):315–319. doi: 10.1038/sj.bmt.1703661.
   PubMed Web of Science ®Google Scholar
• Emery VC, Sabin CA, Cope AV, et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet. 2000;355(9220):2032–2036. doi: 10.1016/S0140-6736(00)02350-3.
   PubMed Web of Science ®Google Scholar
• Razonable RR, Paya CV, Smith TF. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients. J Clin Microbiol. 2002;40(3):746–752. doi: 10.1128/JCM.40.3.746-752.2002.
   PubMed Web of Science ®Google Scholar
• Gerna G, Lilleri D, Caldera D, et al. Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2008;41(10):873–879. doi: 10.1038/sj.bmt.1705986.
   PubMed Web of Science ®Google Scholar
• Verkruyse LA, Storch GA, Devine SM, et al. Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load ≥10000 copies/ml: a safe and effective strategy for allogeneic stem cell transplant patients. Bone Marrow Transplant. 2005;37(1):51–56. doi: 10.1038/sj.bmt.1705213.
   Web of Science ®Google Scholar
• Harrington SM, Buller RS, Storch GA, et al. The effect of quantification standards used in real-time CMV PCR assays on guidelines for initiation of therapy in allogeneic stem cell transplant patients. Bone Marrow Transplant. 2007;39(4):237–238. doi: 10.1038/sj.bmt.1705558.
   PubMed Web of Science ®Google Scholar
• Lilleri D, Gerna G, Furione M, et al. Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem-cell transplantation compared with qualitative pp65 antigenemia. Blood. 2007;110(7):2757–2760. doi: 10.1182/blood-2007-03-080820.
   PubMed Web of Science ®Google Scholar
• Schmidt-Hieber M, Tridello G, Ljungman P, et al. The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the infectious diseases working party of EBMT. Ann Hematol. 2019;98(7):1755–1763. doi: 10.1007/s00277-019-03669-z.
   PubMed Web of Science ®Google Scholar
• Lee J-H, Kalejta RF. Human cytomegalovirus enters the primary CD34 + hematopoietic progenitor cells where it establishes latency by macropinocytosis. J Virol. 2019;93(15):e00452-19. doi: 10.1128/JVI.00452-19.
   PubMed Web of Science ®Google Scholar
• Bieniek R, Kirby JE, Cheng A, et al. Effective use of PCR for the detection of cytomegalovirus viremia and monitoring therapy in immunocompromised patients. Lab Med. 2011;42(6):339–343. doi: 10.1309/LMP4IL3XGU6MQJCE.
   Google Scholar